Core Viewpoint - The announcement indicates that the clinical trial for the innovative drug CKBA ointment for vitiligo has shown positive efficacy and safety, supporting further development into Phase III trials [1] Company Summary - TianKang (301263) announced the completion of data organization and unblinding for the Phase II clinical trial of CKBA ointment [1] - The trial results indicate that CKBA ointment has demonstrated positive effects in non-segmental vitiligo patients, achieving expected goals [1] - The company plans to submit relevant research data to the CDE for breakthrough therapy application and clinical registration communication [1] Industry Summary - The successful results of the CKBA ointment trial may enhance the company's position in the dermatological treatment market, particularly for vitiligo [1] - The ongoing development of innovative drugs in the industry reflects a growing focus on addressing unmet medical needs in dermatology [1]
泰恩康：CKBA软膏白癜风适应症获得II期临床试验研究初步结果且达到预期目标